Biomedical Bonding (BMB) secured an additional patent in China based on a unique primer formulation for use together with its resin-based composite technology directly on wet bone substrates or metal implants.
The patent in China is a step toward the commercialization of BMB’s Bonevolent™ line of products for fracture fixation. Bonevolent technology is customizable by the surgeon and enables patient-specific adaptation to the fracture and bone geometry. The technology is also biocompatible and does not cause irritation or soft tissue adhesion.
“BMB continues to expand its Bonevolent™ IPR portfolio in key geographical positions…China is considered as an attractive market for the company’s fracture fixation products. With this patent approved, the IPR for our primer technology is further strengthened as it protects all key components facilitating exceptional resins-based fixation of bones, metal or teeth. As a company, such approval is a crucial element and allows BMB to pursue the commercialization of its composite-based fixators towards patient-customized treatment of both bone fractures as well dental restorations,” said Founder and CEO, Prof. Michael Malkoch.
Biomedical Bonding (BMB) secured an additional patent in China based on a unique primer formulation for use together with its resin-based composite technology directly on wet bone substrates or metal implants.
The patent in China is a step toward the commercialization of BMB’s Bonevolent™ line of products for fracture fixation. Bonevolent...
Biomedical Bonding (BMB) secured an additional patent in China based on a unique primer formulation for use together with its resin-based composite technology directly on wet bone substrates or metal implants.
The patent in China is a step toward the commercialization of BMB’s Bonevolent™ line of products for fracture fixation. Bonevolent technology is customizable by the surgeon and enables patient-specific adaptation to the fracture and bone geometry. The technology is also biocompatible and does not cause irritation or soft tissue adhesion.
“BMB continues to expand its Bonevolent™ IPR portfolio in key geographical positions…China is considered as an attractive market for the company’s fracture fixation products. With this patent approved, the IPR for our primer technology is further strengthened as it protects all key components facilitating exceptional resins-based fixation of bones, metal or teeth. As a company, such approval is a crucial element and allows BMB to pursue the commercialization of its composite-based fixators towards patient-customized treatment of both bone fractures as well dental restorations,” said Founder and CEO, Prof. Michael Malkoch.
Copy to clipboard 
